Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-07-16
DOI
10.3389/fimmu.2019.01613
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies
- (2019) Nirav N. Shah et al. Frontiers in Oncology
- Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma
- (2019) Chuang Sun et al. Oncotarget
- GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells
- (2019) Eric L. Smith et al. Science Translational Medicine
- CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape
- (2019) Mohamad Hamieh et al. NATURE
- Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma
- (2019) Tiantian Ma et al. ANNALS OF HEMATOLOGY
- B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma
- (2019) Adam D. Cohen et al. JOURNAL OF CLINICAL INVESTIGATION
- BCMA CAR T cells: the winding path to success
- (2019) Ivan Borrello et al. JOURNAL OF CLINICAL INVESTIGATION
- Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma
- (2019) Cesar Sommer et al. MOLECULAR THERAPY
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma
- (2019) Jie Xu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CARs and other T cell therapies for MM: The clinical experience
- (2018) Sophia Danhof et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
- (2018) Jennifer N. Brudno et al. JOURNAL OF CLINICAL ONCOLOGY
- The expansion of targetable biomarkers for CAR T cell therapy
- (2018) Michelle H. Townsend et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation
- (2018) Anna Capsomidis et al. MOLECULAR THERAPY
- Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
- (2018) Margherita Norelli et al. NATURE MEDICINE
- Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design
- (2018) Esther Drent et al. PLoS One
- Extracellular NGFR Spacers Allow Efficient Tracking and Enrichment of Fully Functional CAR-T Cells Co-Expressing a Suicide Gene
- (2018) Monica Casucci et al. Frontiers in Immunology
- A Phase I Study to Assess the Safety and Pharmacokinetics of Single-Agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56 Positive Multiple Myeloma
- (2018) Sikander Ailawadhi et al. Clinical Lymphoma Myeloma & Leukemia
- APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications
- (2018) Yu-Tzu Tai et al. LEUKEMIA
- Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells
- (2018) Na An et al. MOLECULAR PHARMACEUTICS
- Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
- (2018) Shih-Feng Cho et al. Frontiers in Immunology
- Teaching an old dog new tricks: next-generation CAR T cells
- (2018) Nicholas Tokarew et al. BRITISH JOURNAL OF CANCER
- Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting
- (2018) Antonia Rotolo et al. CANCER CELL
- The role of surface molecule CD229 in Multiple Myeloma
- (2018) Michael Olson et al. CLINICAL IMMUNOLOGY
- A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
- (2018) Wan-Hong Zhao et al. Journal of Hematology & Oncology
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
- (2018) Susanne H. Baumeister et al. Cancer Immunology Research
- CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
- (2018) Fabio Morandi et al. Frontiers in Immunology
- Chimeric antigen receptor transduced T cells: Tuning up for the next generation
- (2017) Maria-Luisa Schubert et al. INTERNATIONAL JOURNAL OF CANCER
- A compound chimeric antigen receptor strategy for targeting multiple myeloma
- (2017) K H Chen et al. LEUKEMIA
- A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization
- (2017) Esther Drent et al. MOLECULAR THERAPY
- SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin
- (2017) Jun Chen et al. NATURE
- Therapeutic T cell engineering
- (2017) Michel Sadelain et al. NATURE
- The activated conformation of integrin β7 is a novel multiple myeloma–specific target for CAR T cell therapy
- (2017) Naoki Hosen et al. NATURE MEDICINE
- CD56 in the Immune System: More Than a Marker for Cytotoxicity?
- (2017) Heleen H. Van Acker et al. Frontiers in Immunology
- T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
- (2016) S. A. Ali et al. BLOOD
- APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment
- (2016) Y.-T. Tai et al. BLOOD
- Chimeric Antigen Receptor (CAR) therapy for multiple myeloma
- (2016) Djordje Atanackovic et al. BRITISH JOURNAL OF HAEMATOLOGY
- Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
- (2016) E. Drent et al. HAEMATOLOGICA
- Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
- (2016) Michael Ghermezi et al. HAEMATOLOGICA
- Clinical responses with T lymphocytes targeting malignancy-associated κ light chains
- (2016) Carlos A. Ramos et al. JOURNAL OF CLINICAL INVESTIGATION
- Differentiation stage of myeloma plasma cells: biological and clinical significance
- (2016) B Paiva et al. LEUKEMIA
- Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
- (2016) E. Drent et al. HAEMATOLOGICA
- Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
- (2016) Michael Ghermezi et al. HAEMATOLOGICA
- CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
- (2015) S. L. Maude et al. BLOOD
- Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents
- (2015) Vittorio Emanuele Muccio et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
- (2015) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- Genotoxic Stress Induces Senescence-Associated ADAM10-Dependent Release of NKG2D MIC Ligands in Multiple Myeloma Cells
- (2015) Alessandra Zingoni et al. JOURNAL OF IMMUNOLOGY
- NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
- (2015) Aaron P Rapoport et al. NATURE MEDICINE
- Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
- (2015) Alfred L. Garfall et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
- (2015) David L. Porter et al. Science Translational Medicine
- CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma
- (2015) Sara Yousef et al. Human Vaccines & Immunotherapeutics
- NKG2D Receptor and Its Ligands in Host Defense
- (2015) L. L. Lanier Cancer Immunology Research
- Genetic Modification of T Cells Redirected toward CS1 Enhances Eradication of Myeloma Cells
- (2014) J. Chu et al. CLINICAL CANCER RESEARCH
- CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma
- (2013) M. Casucci et al. BLOOD
- Zoom Zoom: Racing CARs for Multiple Myeloma
- (2013) M. V. Maus et al. CLINICAL CANCER RESEARCH
- Potential therapeutic biomarkers in plasma cell myeloma: A flow cytometry study
- (2013) Wenli Zheng et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
- (2013) J Chu et al. LEUKEMIA
- Chemotherapy stimulates syndecan-1 shedding: A potentially negative effect of treatment that may promote tumor relapse
- (2013) Vishnu C. Ramani et al. MATRIX BIOLOGY
- Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells
- (2013) Hua Jiang et al. Molecular Oncology
- CD56 marks human dendritic cell subsets with cytotoxic potential
- (2013) Dessie Roothans et al. OncoImmunology
- Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma
- (2012) A. Chaidos et al. BLOOD
- Abstract 3499: CD56 targeted chimeric antigen receptors for immunotherapy of multiple myeloma
- (2012) Reuben Benjamin et al. CANCER RESEARCH
- Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma
- (2012) P C Schuberth et al. GENE THERAPY
- Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide
- (2012) YAWARA KAWANO et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Interleukin-15-Induced CD56+ Myeloid Dendritic Cells Combine Potent Tumor Antigen Presentation with Direct Tumoricidal Potential
- (2012) Sébastien Anguille et al. PLoS One
- SLAM Family Receptors and SAP Adaptors in Immunity
- (2011) Jennifer L. Cannons et al. Annual Review of Immunology
- Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)
- (2011) A. Palumbo et al. BLOOD
- T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies
- (2011) D. R. Shaffer et al. BLOOD
- Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma
- (2011) D. Atanackovic et al. HAEMATOLOGICA
- T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells
- (2011) K Mihara et al. LEUKEMIA
- Dll1/Notch activation accelerates multiple myeloma disease development by promoting CD138+ MM-cell proliferation
- (2011) D Xu et al. LEUKEMIA
- Multiple Myeloma
- (2011) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen
- (2010) S Peinert et al. GENE THERAPY
- Expression of SLAM (CD150) cell-surface receptors on human B-cell subsets: From pro-B to plasma cells
- (2010) Jose De Salort et al. IMMUNOLOGY LETTERS
- APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop
- (2009) Jérôme Moreaux et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Regulation of multiple myeloma survival and progression by CD1d
- (2008) E. Spanoudakis et al. BLOOD
- Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance
- (2008) W. Matsui et al. CANCER RESEARCH
- CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
- (2008) E. D. Hsi et al. CLINICAL CANCER RESEARCH
- Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy
- (2008) Gema Mateo et al. JOURNAL OF CLINICAL ONCOLOGY
- NKG2D ligands in tumor immunity
- (2008) N Nausch et al. ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search